Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Jade Biosciences announced the first participant has been dosed in the first-in-human Phase 1 clinical trial of JADE201. JADE201 is a novel, half-life extended, afucosylated anti-BAFF receptor monoclonal antibody designed to deplete B cells via a dual mechanism of action.
Key figures
- Drug Name
- JADE201
- Phase Of Trial
- Phase 1
- Target
- BAFF-R
- Mechanism
- afucosylated monoclonal antibody
- Interim data expected
- 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.